Allergan's BOTOX Wins FDA Nod For Neurologic Condition-Associated Pediatric Detrusor Overactivity
- The FDA has approved Allergan and AbbVie Inc's (NYSE: ABBV) BOTOX (onabotulinumtoxinA). It is used to treat detrusor (bladder muscle) overactivity associated with a neurologic condition in pediatric patients five years of age and older who have an inadequate response to or are intolerant of anticholinergic medication.
- Neurogenic detrusor overactivity occurs when the spinal cord and bladder are not able to communicate effectively. As a result, the bladder muscle involuntarily contracts, increasing the bladder's pressure and reducing the bladder capacity, which can cause the individual to leak urine frequently and unexpectedly.
- Price Action: ABBV share are down 0.68% at $104.68 on the last check Wednesday.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
